Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
| Revenue (Most Recent Fiscal Year) | $102.48M |
| Net Income (Most Recent Fiscal Year) | $-191.09M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.10 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -186.54% |
| Net Margin (Trailing 12 Months) | -186.45% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -79.02% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.01 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.01 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-15.43 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | $-22.49 |
| Diluted Earnings per Share (Trailing 12 Months) | $-26.10 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 16.57M |
| Free Float | 15.59M |
| Market Capitalization | $522.70M |
| Average Volume (Last 20 Days) | 0.23M |
| Beta (Past 60 Months) | 1.31 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.99% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |